Evaxion Biotech A/S
NASDAQ:EVAX

Watchlist Manager
Evaxion Biotech A/S Logo
Evaxion Biotech A/S
NASDAQ:EVAX
Watchlist
Price: 6.21 USD -3.72% Market Closed
Market Cap: 39.2m USD

Wall Street
Price Targets

EVAX Price Targets Summary
Evaxion Biotech A/S

Wall Street analysts forecast EVAX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EVAX is 12.58 USD with a low forecast of 10.1 USD and a high forecast of 16.8 USD.

Lowest
Price Target
10.1 USD
63% Upside
Average
Price Target
12.58 USD
103% Upside
Highest
Price Target
16.8 USD
171% Upside
Evaxion Biotech A/S Competitors:
Price Targets
OXB
Oxford BioMedica PLC
20% Upside
ENTA
Enanta Pharmaceuticals Inc
32% Upside
145020
Hugel Inc
72% Upside
IMTX
Immatics NV
85% Upside
MRSN
Mersana Therapeutics Inc
19% Upside
ARWR
Arrowhead Pharmaceuticals Inc
15% Downside
KURA
Kura Oncology Inc
229% Upside
2696
Shanghai Henlius Biotech Inc
57% Upside

Revenue
Forecast

Revenue Estimate
Evaxion Biotech A/S

The compound annual growth rate of Evaxion Biotech A/S's revenue for the next 4 years is 65%.

N/A
Past Growth
65%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Evaxion Biotech A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Beat

Net Income
Forecast

Net Income Estimate
Evaxion Biotech A/S

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-93%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EVAX's stock price target?
Price Target
12.58 USD

According to Wall Street analysts, the average 1-year price target for EVAX is 12.58 USD with a low forecast of 10.1 USD and a high forecast of 16.8 USD.

What is Evaxion Biotech A/S's Revenue forecast?
Projected CAGR
65%

The compound annual growth rate of Evaxion Biotech A/S's revenue for the next 4 years is 65%.

Back to Top